Department of Radiology, Uijeongbu St. Mary's Hospital, Seoul, Republic of Korea.
Department of Dermatology, Uijeongbu St. Mary's Hospital, Seoul, Republic of Korea.
J Am Acad Dermatol. 2018 Mar;78(3):464-470.e2. doi: 10.1016/j.jaad.2017.09.035. Epub 2017 Sep 25.
Many studies have shown a link between inflammation and cancer development. However, there are few studies regarding the correlation between Behçet disease (BD) and cancer.
To determine the overall cancer risk and risk for specific cancers in patients with BD.
Patients with BD (n = 14,137; mean age, 44.2 ± 12.5 years; male patients, 32.4%) without known previous cancer were selected from the Korean National Health Insurance Database between 2007 and 2014. An age- and sex-matched control population of individuals without BD was randomly sampled at a ratio of 10:1. Both cohorts were followed for incident cancer until 2015.
Overall, cancer was newly diagnosed in 451 patients with BD (3.19%) and 3975 controls (2.81%) during the follow-up period. Patients with BD showed a significantly higher risk for cancer compared with the controls (hazard ratio [HR], 1.134; 95% confidence interval [CI], 1.029-1.25), leukemia (HR, 5.801; 95% CI, 3.24-10.385), lymphoma (HR, 2.584; 95% CI, 1.559-4.283), oral cavity and pharyngeal cancer (HR, 2.113; 95% CI, 1.102-4.052), thyroid cancer (HR, 1.256; 95% CI, 1.05-1.501), and prostate cancer (HR, 1.784; 95% CI, 1.141-2.791).
The treatment or severity of diseases in each individual was not examined.
Patients with BD had a higher risk for overall cancer compared with controls without BD. Physicians should carefully monitor patients with BD for the potential development of malignancies.
许多研究表明炎症与癌症发展之间存在关联。然而，关于贝切特病（BD）与癌症之间的相关性的研究甚少。
确定 BD 患者的总体癌症风险和特定癌症的风险。
从 2007 年至 2014 年，从韩国国家健康保险数据库中选择了 14137 名（平均年龄 44.2±12.5 岁；男性患者 32.4%）无已知先前癌症的 BD 患者。以 10:1 的比例随机抽取无 BD 的年龄和性别匹配的对照组个体。两个队列均随访至 2015 年，以观察新发癌症。
在随访期间，BD 患者中有 451 例（3.19%）和对照组中有 3975 例（2.81%）新诊断出癌症。与对照组相比，BD 患者的癌症风险显著更高（风险比 [HR]，1.134；95%置信区间 [CI]，1.029-1.25），白血病（HR，5.801；95%CI，3.24-10.385），淋巴瘤（HR，2.584；95%CI，1.559-4.283），口腔和咽部癌症（HR，2.113；95%CI，1.102-4.052），甲状腺癌（HR，1.256；95%CI，1.05-1.501）和前列腺癌（HR，1.784；95%CI，1.141-2.791）。
未检查每个个体的疾病治疗或严重程度。
与无 BD 的对照组相比，BD 患者的总体癌症风险更高。医生应仔细监测 BD 患者潜在恶性肿瘤的发生。
Zotero 插件